CN114246917A - 一种缓解心脑血管疾病生物药剂及生产方法 - Google Patents
一种缓解心脑血管疾病生物药剂及生产方法 Download PDFInfo
- Publication number
- CN114246917A CN114246917A CN202210185014.XA CN202210185014A CN114246917A CN 114246917 A CN114246917 A CN 114246917A CN 202210185014 A CN202210185014 A CN 202210185014A CN 114246917 A CN114246917 A CN 114246917A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicinal composition
- composition
- twenty
- medicinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 29
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 29
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 title claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 30
- 239000003124 biologic agent Substances 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 15
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 14
- 229930064664 L-arginine Natural products 0.000 claims abstract description 13
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 13
- 244000046052 Phaseolus vulgaris Species 0.000 claims abstract description 12
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims abstract description 12
- 239000000052 vinegar Substances 0.000 claims abstract description 12
- 235000021419 vinegar Nutrition 0.000 claims abstract description 12
- 235000013557 nattō Nutrition 0.000 claims abstract description 11
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 9
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 9
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 9
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 9
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 9
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 9
- 229940026314 red yeast rice Drugs 0.000 claims abstract description 9
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 8
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 8
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 8
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 8
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 8
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 8
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 8
- 240000000171 Crataegus monogyna Species 0.000 claims abstract description 8
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 8
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 8
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 8
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 8
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 8
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 8
- 244000099147 Ananas comosus Species 0.000 claims abstract description 7
- 235000007119 Ananas comosus Nutrition 0.000 claims abstract description 7
- 244000236658 Paeonia lactiflora Species 0.000 claims abstract description 6
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims abstract description 6
- 241000736199 Paeonia Species 0.000 claims abstract description 4
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims description 127
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 239000000706 filtrate Substances 0.000 claims description 24
- 238000001035 drying Methods 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 21
- 239000000284 extract Substances 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 19
- 238000004140 cleaning Methods 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 11
- 235000011201 Ginkgo Nutrition 0.000 claims description 9
- 244000194101 Ginkgo biloba Species 0.000 claims description 9
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 9
- 238000000855 fermentation Methods 0.000 claims description 9
- 230000004151 fermentation Effects 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 8
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 8
- 241000545744 Hirudinea Species 0.000 claims description 8
- 240000000249 Morus alba Species 0.000 claims description 8
- 235000008708 Morus alba Nutrition 0.000 claims description 8
- 235000006533 astragalus Nutrition 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 235000012907 honey Nutrition 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 241000382455 Angelica sinensis Species 0.000 claims description 5
- 241000045403 Astragalus propinquus Species 0.000 claims description 5
- 241000219784 Sophora Species 0.000 claims description 4
- 244000046101 Sophora japonica Species 0.000 claims description 4
- 235000010586 Sophora japonica Nutrition 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000004744 fabric Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 230000001376 precipitating effect Effects 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 239000004575 stone Substances 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 235000014493 Crataegus Nutrition 0.000 claims 1
- 241001092040 Crataegus Species 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 108010004032 Bromelains Proteins 0.000 abstract description 4
- 239000004365 Protease Substances 0.000 abstract description 4
- 210000004204 blood vessel Anatomy 0.000 abstract description 4
- 235000019835 bromelain Nutrition 0.000 abstract description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 4
- 208000007536 Thrombosis Diseases 0.000 abstract description 3
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 229940057059 monascus purpureus Drugs 0.000 abstract description 3
- 238000004220 aggregation Methods 0.000 abstract description 2
- 230000002776 aggregation Effects 0.000 abstract description 2
- 210000001772 blood platelet Anatomy 0.000 abstract description 2
- 230000036770 blood supply Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 abstract description 2
- 235000012000 cholesterol Nutrition 0.000 abstract description 2
- -1 lipid peroxide Chemical class 0.000 abstract description 2
- 230000002107 myocardial effect Effects 0.000 abstract description 2
- 235000015097 nutrients Nutrition 0.000 abstract description 2
- 239000013589 supplement Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 244000132619 red sage Species 0.000 description 6
- 241001106477 Paeoniaceae Species 0.000 description 4
- 244000061520 Angelica archangelica Species 0.000 description 3
- 241001061264 Astragalus Species 0.000 description 3
- 235000001287 Guettarda speciosa Nutrition 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000004233 talus Anatomy 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000005866 Lime sulphur Substances 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 241000913745 Spatholobus Species 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
- JNVCSEDACVAATK-UHFFFAOYSA-L [Ca+2].[S-]SSS[S-] Chemical compound [Ca+2].[S-]SSS[S-] JNVCSEDACVAATK-UHFFFAOYSA-L 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000002892 effect on hypertension Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- 229940086319 nattokinase Drugs 0.000 description 1
- 108010073682 nattokinase Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/13—Preparation or pretreatment of starting material involving cleaning, e.g. washing or peeling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Insects & Arthropods (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Animal Husbandry (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种缓解心脑血管疾病生物药剂及生产方法,生物药剂包括第一药物组合物、第二药物组合物和第三药物组合物,所述第一药物组合物的原材料由纳豆、醋豆、红曲、菠萝酵素和L‑精氨酸组成,所述第二药物组合物的原材料由丹参、川芎、三七、桃仁、山楂、红花、丹皮、川芍、白芍和赤芍组成。本发明通过在药片剂中纳豆、醋豆、红曲、菠萝酵素和L‑精氨酸药物的添加,可减少患者血小板聚集并压制过氧化脂质的产生降血粘,且分解胆固醇溶解陈旧血栓并降血脂,并激活细胞动力并修复血管内壁弹性增加血流量,同时还可增强心肌供血、补充营养元素和强化机体功能的作用。
Description
技术领域
本发明涉及药物制剂领域,特别涉及一种缓解心脑血管疾病生物药剂及生产方法。
背景技术
心脑血管疾病是心脏血管和脑血管疾病的统称,泛指由于高脂血症、血液黏稠、动脉粥样硬化、高血压等所导致的心脏、大脑及全身组织发生的缺血性或出血性疾病。心脑血管疾病是一种严重威胁人类,特别是50岁以上中老年人健康的常见病,具有高患病率、高致残率和高死亡率的特点,即使应用目前最先进、完善的治疗手段,仍可有50%以上的脑血管意外幸存者生活不能完全自理,全世界每年死于心脑血管疾病的人数高达1500万人,居各种死因首位。对于心脑血管疾病治疗市面上存在各种各样的治疗药物。但是传统治疗药物,如阿司匹林(西药)减少血小板的聚集(降低血粘),丹参、银杏等化学化瘀的药物减少红细胞数量并调节血脂,链激酶、尿激酶(溶栓药物)只能抢救时用,然而,这些药物无法对患者起到很好的缓解作用,且不同的药物只能对应治疗不同的问题,无法实现对心脑血管疾病的全面性治疗,从而降低了对心脑血管患者的治疗效果。
发明内容
本发明的主要目的在于提供一种缓解心脑血管疾病生物药剂及生产方法,可以有效解决背景技术中的问题。
为实现上述目的,本发明采取的技术方案为:
一种缓解心脑血管疾病生物药剂的配方,包括第一药物组合物、第二药物组合物和第三药物组合物,第一药物组合物的原材料由纳豆、醋豆、红曲、菠萝酵素和L-精氨酸组成,第二药物组合物的原材料由丹参、川芎、三七、桃仁、山楂、红花、丹皮、川芍、白芍和赤芍组成,第三药物组合物的原材料由黄芪、银杏叶、桑枝、桂枝、槐花、当归、鸡血藤、蜂蜜和水蛭组成。
优选的,第一药物组合物中:纳豆的重量份数为二十五份至六十五份,醋豆的重量份数为二十二份至三十一份,红曲的重量份数为十四份至二十五份,菠萝酵素的重量份数为十三份至二十一份,L-精氨酸重量份数为十五份至二十七份。
优选的,第二药物组合物中:丹参的重量份数为十五份至四十份,川芎的重量份数为五份至二十份,三七的重量份数为八份至二十二份,桃仁的重量份数为十份至二十份,山楂的重量份数为十五份至二十五份,红花的重量份数为四份至十二份,丹皮的重量份数为二十份至三十份,川芍的重量份数为十份至三十份,白芍的重量份数为三份至十五份,赤芍的重量份数为十份至三十份。
优选的,第三药物组合物中:黄芪的重量份数为三十份至一百二十份,银杏叶的重量份数为十份至六十份,桑枝的重量份数为三份至十份,桂枝的重量份数为十份至十五份,槐花的重量份数配为五份至五十份,当归的重量份数为五份至三十份,鸡血藤的重量份数为十份至九十份,蜂蜜的重量份数为一百份至二百二十份,水蛭的重量份数为五份至十五份。
优选的,第一药物组合物、第二药物组合物和第三药物组合物的重量份数均以克、两、斤或公斤的重量计算单位为准。
优选的,第一药物组合物、第二药物组合物和第三药物组合物的重量份数配比为5:2:1。
一种缓解心脑血管疾病生物药剂的生产方法,包括以下流程:
步骤一:原材料准备,按重量份数配比依次选用第一药物组合物、第二药物组合物和第三药物组合物中的各个药材,并将选取后的药材分别投入第一清洗设备、第二清洗设备和第三清洗设备中清洗干净;
步骤二:煎煮过滤处理,将清洗后的第一药物组合物、第二药物组合物和第三药物组合物晾干后分别投入第一煎药机、第二煎药机和第三煎药机内煎煮三小时,并取出煎煮液后再次加热煎煮,如此反复三次,合并三次煎煮液,再通过200目滤布过滤得到滤液,滤液减压浓缩至相对密度1.5,经石硫法处理后用乙醇沉淀二次,取上清液,回收乙醇,并浓缩至相对密度1.2~1.5,得到第一药物组合物、第二药物组合物和第三药物组合物的浸膏;
步骤三:发酵处理,将得到的第一药物组合物、第二药物组合物和第三药物组合物的浸膏置于温度为28-32℃、湿度为50-70%的发酵罐中密封发酵20-30天,得到浸膏发酵物;
步骤四:干燥粉碎处理,将得到的第一药物组合物、第二药物组合物和第三药物组合物的发酵物放入干燥设备内进行干燥处理,且干燥设备的温度设置在80-100℃,干燥时间设置在30-60min,得到固态的浸膏,并将固态的第一药物组合物、第二药物组合物和第三药物组合物的浸膏投入粉碎设备中进行粉碎处理,得到浸膏粉;
步骤五:混合制粒处理,将得到的第一药组合物、第二药物组合物和第三药物组合物的浸膏粉投入至混合搅拌设备内,并向混合搅拌设备内投入混合物总重为0.5-5%的羧甲基淀粉钠混合均匀,再用70%乙醇制粒,干燥后得到整粒;
步骤六:制成片剂:取甘油溶解于无水乙醇中并搅拌均匀,搅拌均匀后投入喷洒在步骤五得到的颗粒中,混合40分钟压片,得到片剂。
优选的,步骤五中搅拌设备的转数设置在3500r/min,搅拌时间设置在15-30min。
优选的,步骤二中,滤液减压浓缩至相对密度1.5是在滤液温度100℃的条件下的相对密度值;取上清液,回收乙醇,并浓缩至相对密度1.2~1.5,是在滤液温度80℃的条件下的相对密度值。
与现有技术相比,本发明具有如下有益效果:
本发明中,通过在药片剂中纳豆、醋豆、红曲、菠萝酵素和L-精氨酸药物的添加,可减少患者血小板聚集并压制过氧化脂质的产生降血粘,且分解胆固醇溶解陈旧血栓并降血脂,并激活细胞动力并修复血管内壁弹性增加血流量,同时还可增强心肌供血、补充营养元素和强化机体功能的作用,相对比传统的治疗药物,实现对心脑血管疾病的兼预防与治疗为一体,且有效、安全和方便,既能溶解陈旧血栓、无抗凝血反应、复发率低、对血压无影响之功效,且设置的第二药物组合物和第三药物组合物用作于辅助治疗,通过各个药材自身的功效来辅助治疗心脑血管疾病,整个药片剂的使用可实现对心脑血管疾病的全方面治疗,并提高对患者的治疗效果。
附图说明
图1为本发明的生产方法流程图。
具体实施方式
为使本发明实现的技术手段、创作特征、达成目的与功效易于明白了解,下面结合具体实施方式,进一步阐述本发明。
实施例一:
如图1所示,一种缓解心脑血管疾病生物药剂的配方,包括第一药物组合物、第二药物组合物和第三药物组合物,第一药物组合物的原材料由纳豆、醋豆、红曲、菠萝酵素和L-精氨酸组成,第一药物组合物中:纳豆的重量份数为二十五份至六十五份,醋豆的重量份数为二十二份至三十一份,红曲的重量份数为十四份至二十五份,菠萝酵素的重量份数为十三份至二十一份,L-精氨酸的重量份数为十五份至二十七份,第二药物组合物的原材料由丹参、川芎、三七、桃仁、山楂、红花、丹皮、川芍、白芍和赤芍组成,第二药物组合物中:丹参的重量份数为十五份至四十份,川芎的重量份数为五份至二十份,三七的重量份数为八份至二十二份,桃仁的重量份数为十份至二十份,山楂的重量份数为十五份至二十五份,红花的重量份数为四份至十二份,丹皮的重量份数为二十份至三十份,川芍的重量份数为十份至三十份,白芍的重量份数为三份至十五份,赤芍的重量份数为十份至三十份,第三药物组合物的原材料由黄芪、银杏叶、桑枝、桂枝、槐花、当归、鸡血藤、蜂蜜和水蛭组成,第三药物组合物中:黄芪的重量份数为三十份至一百二十份,银杏叶的重量份数为十份至六十份,桑枝的重量份数为三份至十份,桂枝的重量份数为十份至十五份,槐花的重量份数配为五份至五十份,当归的重量份数为五份至三十份,鸡血藤的重量份数为十份至九十份,蜂蜜的重量份数为一百份至二百二十份,水蛭的重量份数为五份至十五份,第一药物组合物、第二药物组合物和第三药物组合物的重量份数均以克、两、斤或公斤的重量计算单位为准,第一药物组合物、第二药物组合物和第三药物组合物的重量份数配比为:5:2:1,其中第一药物组合物(纳豆、醋豆、红曲、菠萝酵素和L-精氨酸),纳豆中含纳豆激酶、纳豆菌、维生素K2、优质蛋白质等数十种活性物质;红曲具有活血化淤、健脾消食等功效;醋豆对高血压、便秘和心脏病等多种疾病有良好的疗效;L-精氨酸是一种很强的舒张血管物质,在维持血管张力的恒定和调节血压的稳定性中起着重要作用。L-精氨酸是NO生成的前体,补充L-精氨酸促进NO的生成,可促进血管扩张和血管生成。血管扩张从而促使血液流向人体的各个部位,起到保持血管清洁、维持正常血压、预防心脏病的效果。而第二药物组合物(丹参、川芎、三七、桃仁、山楂、红花、丹皮、川芍、白芍和赤芍)和第三药物组合物(黄芪、银杏叶、桑枝、桂枝、槐花、当归、鸡血藤、蜂蜜和水蛭)则由各个药材自身携带的功效辅助配合第一药物组合物的使用。
实施例二:
一种缓解心脑血管疾病生物药剂的生产方法,包括以下流程:
步骤一:原材料准备,按重量份数配比依次选用第一药物组合物、第二药物组合物和第三药物组合物中的各个药材,并将选取后的药材分别投入第一清洗设备、第二清洗设备和第三清洗设备中清洗干净;
骤二:煎煮过滤处理,将清洗后的第一药物组合物、第二药物组合物和第三药物组合物晾干后分别投入第一煎药机、第二煎药机和第三煎药机内煎煮三小时,并取出煎煮液后再次加热煎煮,如此反复三次,合并三次煎煮液,再通过200目滤布过滤得到滤液,滤液减压浓缩至相对密度1.5,经石硫法处理后用乙醇沉淀二次,取上清液,回收乙醇,并浓缩至相对密度1.2~1.5,得到第一药物组合物、第二药物组合物和第三药物组合物的浸膏;
步骤三:发酵处理,将得到的第一药物组合物、第二药物组合物和第三药物组合物的浸膏置于温度为28-32℃、湿度为50-70%的发酵罐中密封发酵20-30天,得到浸膏发酵物;
步骤四:干燥粉碎处理,将得到的第一药物组合物、第二药物组合物和第三药物组合物的发酵物放入干燥设备内进行干燥处理,且干燥设备的温度设置在80-100℃,干燥时间设置在30-60min,得到固态的浸膏,并将固态的第一药物组合物、第二药物组合物和第三药物组合物的浸膏投入粉碎设备中进行粉碎处理,得到浸膏粉;
步骤五:混合制粒处理,将得到的第一药组合物、第二药物组合物和第三药物组合物的浸膏粉投入至混合搅拌设备内,并向混合搅拌设备内投入混合物总重为0.5-5%的羧甲基淀粉钠混合均匀,再用70%乙醇制粒,干燥后得到整粒;
步骤六:制成片剂:取甘油溶解于无水乙醇中并搅拌均匀,搅拌均匀后投入喷洒在步骤五得到的颗粒中,混合40分钟压片,得到片剂。
步骤五中搅拌设备的转数设置在3500r/min,搅拌时间设置在15-30min。
步骤二中,滤液减压浓缩至相对密度1.5是在滤液温度100℃的条件下的相对密度值;取上清液,回收乙醇,并浓缩至相对密度1.2~1.5,是在滤液温度80℃的条件下的相对密度值。
需要说明的是,本发明为一种缓解心脑血管疾病生物药剂及生产方法,在进行生产制备时,首先将第一药物组合物(纳豆、醋豆、红曲、菠萝酵素和L-精氨酸)、第二药物组合物(丹参、川芎、三七、桃仁、山楂、红花、丹皮、川芍、白芍和赤芍)和第三药物组合物(黄芪、银杏叶、桑枝、桂枝、槐花、当归、鸡血藤、蜂蜜和水蛭)按重量份数配比选用,并将选取后的药材分别投入第一清洗设备、第二清洗设备和第三清洗设备中清洗干净,将清洗后的第一药物组合物、第二药物组合物和第三药物组合物晾干后分别投入第一煎药机、第二煎药机和第三煎药机内煎煮三小时,并取出煎煮液后再次加热煎煮,如此反复三次,合并三次煎煮液,再通过200目滤布过滤得到滤液,滤液减压浓缩至相对密度1.5(滤液温度100℃的条件下),经石硫法处理后用乙醇沉淀二次,取上清液,回收乙醇,并浓缩至相对密度1.2~1.5(滤液温度80℃的条件下),得到第一药物组合物、第二药物组合物和第三药物组合物的浸膏,将得到的第一药物组合物、第二药物组合物和第三药物组合物的浸膏置于温度为28-32℃、湿度为50-70%的发酵罐中密封发酵20-30天,得到浸膏发酵物,将得到的第一药物组合物、第二药物组合物和第三药物组合物的发酵物放入干燥设备内进行干燥处理,且干燥设备的温度设置在80-100℃,干燥时间设置在30-60min,得到固态的浸膏,并将固态的第一药物组合物、第二药物组合物和第三药物组合物的浸膏投入粉碎设备中进行粉碎处理,得到浸膏粉,将得到的第一药组合物、第二药物组合物和第三药物组合物的浸膏粉投入至混合搅拌设备内,并向混合搅拌设备内投入混合物总重为0.5-5%的羧甲基淀粉钠混合均匀,搅拌设备的转数设置在3500r/min,搅拌时间设置在15-30min,再用70%乙醇制粒,干燥后得到整粒,取甘油溶解于无水乙醇中并搅拌均匀,搅拌均匀后投入喷洒在步骤五得到的颗粒中,混合40分钟压片,得到片剂。
综上所述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,然而在不脱离本发明的范围的情况下,可以对其进行各种改进并且可以用等效物替换其中的部件,或者对其中部分技术特征进行等同替换,凡在本发明的精神和原则之内,均应包含在本发明的保护范围之内。
Claims (9)
1.一种缓解心脑血管疾病生物药剂,其特征在于:包括第一药物组合物、第二药物组合物和第三药物组合物,所述第一药物组合物的原材料由纳豆、醋豆、红曲、菠萝酵素和L-精氨酸组成,第二药物组合物的原材料由丹参、川芎、三七、桃仁、山楂、红花、丹皮、川芍、白芍和赤芍组成,第三药物组合物的原材料由黄芪、银杏叶、桑枝、桂枝、槐花、当归、鸡血藤、蜂蜜和水蛭组成。
2.根据权利要求1所述的一种缓解心脑血管疾病生物药剂,其特征在于:所述第一药物组合物中:纳豆的重量份数为二十五份至六十五份,醋豆的重量份数为二十二份至三十一份,红曲的重量份数为十四份至二十五份,菠萝酵素的重量份数为十三份至二十一份,L-精氨酸的重量份数为十五份至二十七份。
3.根据权利要求1所述的一种缓解心脑血管疾病生物药剂,其特征在于:所述第二药物组合物中:丹参的重量份数为十五份至四十份,川芎的重量份数为五份至二十份,三七的重量份数为八份至二十二份,桃仁的重量份数为十份至二十份,山楂的重量份数为十五份至二十五份,红花的重量份数为四份至十二份,丹皮的重量份数为二十份至三十份,川芍的重量份数为十份至三十份,白芍的重量份数为三份至十五份,赤芍的重量份数为十份至三十份。
4.根据权利要求1所述的一种缓解心脑血管疾病生物药剂,其特征在于:所述第三药物组合物中:黄芪的重量份数为三十份至一百二十份,银杏叶的重量份数为十份至六十份,桑枝的重量份数为三份至十份,桂枝的重量份数为十份至十五份,槐花的重量份数为五份至五十份,当归的重量份数为五份至三十份,鸡血藤的重量份数为十份至九十份,蜂蜜的重量份数为一百份至二百二十份,水蛭的重量份数为五份至十五份。
5.根据权利要求1所述的一种缓解心脑血管疾病生物药剂,其特征在于:所述第一药物组合物、第二药物组合物和第三药物组合物的重量份数均以克、两、斤或公斤的重量计算单位为准。
6.根据权利要求5所述的一种缓解心脑血管疾病生物药剂,其特征在于:所述第一药物组合物、第二药物组合物和第三药物组合物的重量份数配比为5:2:1。
7.根据权利要求1-6任一所述的一种缓解心脑血管疾病生物药剂的生产方法,包括以下流程:
步骤一:原材料准备,按重量份数配比依次选用第一药物组合物、第二药物组合物和第三药物组合物中的各个药材,并将选取后的药材分别投入第一清洗设备、第二清洗设备和第三清洗设备中清洗干净;
步骤二:煎煮过滤处理,将清洗后的第一药物组合物、第二药物组合物和第三药物组合物晾干后分别投入第一煎药机、第二煎药机和第三煎药机内煎煮三小时,并取出煎煮液后再次加热煎煮,如此反复三次,合并三次煎煮液,再通过200目滤布过滤得到滤液,滤液减压浓缩至相对密度1.5,经石硫法处理后用乙醇沉淀二次,取上清液,回收乙醇,并浓缩至相对密度1.2~1.5,得到第一药物组合物、第二药物组合物和第三药物组合物的浸膏;
步骤三:发酵处理,将得到的第一药物组合物、第二药物组合物和第三药物组合物的浸膏置于温度为28-32℃、湿度为50-70%的发酵罐中密封发酵20-30天,得到浸膏发酵物;
步骤四:干燥粉碎处理,将得到的第一药物组合物、第二药物组合物和第三药物组合物的发酵物放入干燥设备内进行干燥处理,且干燥设备的温度设置在80-100℃,干燥时间设置在30-60min,得到固态的浸膏,并将固态的第一药物组合物、第二药物组合物和第三药物组合物的浸膏投入粉碎设备中进行粉碎处理,得到浸膏粉;
步骤五:混合制粒处理,将得到的第一药组合物、第二药物组合物和第三药物组合物的浸膏粉投入至混合搅拌设备内,并向混合搅拌设备内投入混合物总重为0.5-5%的羧甲基淀粉钠混合均匀,再用70%乙醇制粒,干燥后得到整粒;
步骤六:制成片剂:取甘油溶解于无水乙醇中并搅拌均匀,搅拌均匀后投入喷洒在步骤五得到的颗粒中,混合40分钟压片,得到片剂。
8.根据权利要求7所述的一种缓解心脑血管疾病生物药剂的生产方法,其特征在于:所述步骤五中搅拌设备的转数设置在3500r/min,搅拌时间设置在15-30min。
9.根据权利要求7所述的一种缓解心脑血管疾病生物药剂的生产方法,其特征在于:步骤二中,滤液减压浓缩至相对密度1.5是在滤液温度100℃的条件下的相对密度值;取上清液,回收乙醇,并浓缩至相对密度1.2~1.5,是在滤液温度80℃的条件下的相对密度值。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210185014.XA CN114246917A (zh) | 2022-02-28 | 2022-02-28 | 一种缓解心脑血管疾病生物药剂及生产方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210185014.XA CN114246917A (zh) | 2022-02-28 | 2022-02-28 | 一种缓解心脑血管疾病生物药剂及生产方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114246917A true CN114246917A (zh) | 2022-03-29 |
Family
ID=80800043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210185014.XA Pending CN114246917A (zh) | 2022-02-28 | 2022-02-28 | 一种缓解心脑血管疾病生物药剂及生产方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114246917A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114470175A (zh) * | 2022-04-14 | 2022-05-13 | 深圳德荫堂生物科技有限公司 | 一种美白抗衰老药物及生产方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103735584A (zh) * | 2014-01-21 | 2014-04-23 | 谢国清 | 治疗心脑血管疾病的中药组合物 |
CN107684077A (zh) * | 2017-10-19 | 2018-02-13 | 厦门翼翔缘生物科技有限公司 | 一种抗氧化保健酵素及其制备方法 |
CN110368487A (zh) * | 2019-08-09 | 2019-10-25 | 上海医盛生物科技发展有限公司 | 一种改善心脑血管健康状况的功能性营养食品 |
CN113368223A (zh) * | 2020-02-25 | 2021-09-10 | 张旺凡 | 一种用于心脑血管病防治的中药复方分散片及制备方法 |
CN113769072A (zh) * | 2021-09-17 | 2021-12-10 | 中科卫康(广东)生物科技研究中心(有限合伙) | 一种具有防治心脑血管疾病功效的功能产品及其制备方法 |
-
2022
- 2022-02-28 CN CN202210185014.XA patent/CN114246917A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103735584A (zh) * | 2014-01-21 | 2014-04-23 | 谢国清 | 治疗心脑血管疾病的中药组合物 |
CN107684077A (zh) * | 2017-10-19 | 2018-02-13 | 厦门翼翔缘生物科技有限公司 | 一种抗氧化保健酵素及其制备方法 |
CN110368487A (zh) * | 2019-08-09 | 2019-10-25 | 上海医盛生物科技发展有限公司 | 一种改善心脑血管健康状况的功能性营养食品 |
CN113368223A (zh) * | 2020-02-25 | 2021-09-10 | 张旺凡 | 一种用于心脑血管病防治的中药复方分散片及制备方法 |
CN113769072A (zh) * | 2021-09-17 | 2021-12-10 | 中科卫康(广东)生物科技研究中心(有限合伙) | 一种具有防治心脑血管疾病功效的功能产品及其制备方法 |
Non-Patent Citations (5)
Title |
---|
《文摘报》编辑部编著: "《家庭保健实用宝典》", 30 September 2011, 光明日报出版社 * |
李朝杰等: "脑心通对急性冠脉综合征患者Hcy、vWF、MMP-3、hs-CRP的影响", 《现代中西医结合杂志》 * |
杨晓惠等: "三七纳豆红曲复配对高脂血症模型大鼠血脂的影响", 《现代食品》 * |
浙江任君逑商贸有限公司: "普罗庭纳豆酵素红曲片都有哪些成分?都有哪些功效适合什么人食用", 《丰铭网》 * |
陈修: "《心血管药理学 第2版》", 30 June 1989, 人民卫生出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114470175A (zh) * | 2022-04-14 | 2022-05-13 | 深圳德荫堂生物科技有限公司 | 一种美白抗衰老药物及生产方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107595893A (zh) | 一种经酶处理的中药饮片及其制备方法 | |
CN112057551A (zh) | 一种具有滋阴补肾功能的组合物及其制备方法和应用 | |
CN102225100A (zh) | 一种治疗心脑血管疾病的中药配方及其产品制备工艺 | |
CN1879601B (zh) | 乌发作用制剂的配方及制备方法 | |
CN114246917A (zh) | 一种缓解心脑血管疾病生物药剂及生产方法 | |
CN111643605A (zh) | 一种治疗心脑血管疾病的中药组合物及其制备方法 | |
CN1199664C (zh) | 治疗心脑血管疾病的中药制剂及其制作方法 | |
CN106962725A (zh) | 一种莲子饮品的制作方法 | |
CN108079219A (zh) | 一种治疗烧烫伤的外用组合物及其制备方法 | |
CN107823293A (zh) | 治疗口腔溃疡的瑶医外用散剂及其制备方法 | |
CN114522213A (zh) | 一种改善记忆力的草本雾化组合物及其制备方法 | |
CN115245202A (zh) | 一种健脾养胃养心的丸剂及其制备方法 | |
KR20210133347A (ko) | 환 형태의 비염 및 기관지염 치료제 | |
CN105362630A (zh) | 一种治疗更年期综合症的药物组合物及其制备方法 | |
CN110613793A (zh) | 一种抗肿瘤组合物及其制备方法和用途 | |
CN116251152B (zh) | 用于生发乌发的中药组合物、中药制剂的制备方法以及应用 | |
CN1321484A (zh) | 治疗冠心病合并高血压的药品及制备工艺 | |
CN102626471A (zh) | 一种具有防敏脱敏、修复再生作用的中药组合物 | |
CN109364113A (zh) | 一种白藜芦醇和中药提取物的组合物和用途 | |
CN107951951B (zh) | 一种祛老年斑的中药组合物及其制备方法 | |
CN105169064A (zh) | 一种用于美白皮肤的药物制剂 | |
CN115772446A (zh) | 一种沉香精油及其制备方法与应用 | |
CN105343688A (zh) | 一种治疗心肌梗塞的药物组合物及其应用 | |
CN112791157A (zh) | 一种治疗肝肾不足的中药制剂及其制备方法 | |
CN105106663A (zh) | 一种用于治疗心律失常的药物制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220329 |
|
RJ01 | Rejection of invention patent application after publication |